ADVANCED COMPREHENSIVE MAGNETIC RESONANCE SOLUTION FOR THE NONINVASIVE CHARACTERIZATION OF HIGH RESOLUTION METABOLIC BIOMARKERS OF RISK IN PATIENTS WITH ALZHEIMER'S DISEASE AND DEMENTIA

先进的综合磁共振解决方案，用于无创表征阿尔茨海默病和痴呆症患者风险的高分辨率代谢生物标志物

• 批准号: 10820517
• 负责人: Ravi Srinivasan
• 金额: $ 56.99万
• 依托单位: ADVANCED IMAGING RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-20 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10820517
• 关键词: 3-Dimensional; Address; Age; Aging; Agreement; Alzheimer disease detection; Alzheimer' s Disease; Alzheimer' s disease patient; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Alzheimer’s disease biomarker; Atrophic; Binding; Bioenergetics; Biological Markers; Brain; Calibration; Clinical; Clinical Trials; Computer software; Custom; Data; Dementia; Development; Devices; Dimensions; Disease Progression; Early Diagnosis; Elderly; Energy Metabolism; Exhibits; Functional Magnetic Resonance Imaging; Goals; Head; Human; Image; Licensing; Link; Magnetic Resonance; Magnetic Resonance Imaging; Maps; Marketing; Measurable; Measurement; Medial; Medical; Mental disorders; Metabolic; Metric System; Minor; Mitochondria; National Institute on Aging; Nicotinamide adenine dinucleotide; Noise; Nuclear; Patients; Pennsylvania; Performance; Phase; Play; Procedures; Process; Protocols documentation; Reproducibility; Research; Research Personnel; Resolution; Risk; Satiation; Scanning; Signal Transduction; Small Business Innovation Research Grant; Spectrum Analysis; Structure; Symptoms; System; Technology; Temporal Lobe; Testing; Time; Tissues; Training; United States National Institutes of Health; Universities; Validation; Vendor; Visualization; Work; absorption; clinical application; commercialization; data acquisition; design; detector; diagnostic tool; high risk; improved; innovation; medical schools; memory process; metabolomics; mild cognitive impairment; nervous system disorder; novel; predictive marker; programs; quality assurance; radio frequency; risk prediction; screening; software development; spectrograph; transmission process

NIH SBIR Fast-Track, PAS-22-196 Advanced Comprehensive Magnetic Resonance Solution for the Non Invasive Characterization of No Clinical Trials High Resolution Metabolic Biomarkers of Risk in Patients with Alzheimer’s Disease and Dementia Project Summary This project addresses the Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Initiative of the National Institute on Aging (PAS-22-196). We propose to develop an advanced hardware-software package, ADRD360, to optimally acquire, process, and analyze magnetic resonance imaging (MRI) and spectroscopy (MRS) in the human brain. The ADRD360 will help to localize metabolic signatures and obtain MRI and MRS brain data at much higher resolutions than currently possible on clinical MR systems. Highly resolved MRI and MRS will be of utmost importance to aid in the early prediction of the risk of developing AD. The ADRD360 may lead to the early detection of structural and metabolic parameters as predictive diagnostic tool biomarkers in patients with AD, ADRD, other neurological disorders and psychiatric diseases. This project will offer a complete solution with the development and optimization of 1) advanced radio-frequency (RF) coils approaching ultimate intrinsic signal-to-noises (UISNRs) and acceptable specific absorption rates (SARs); 2) pushing structural MR imaging resolutions over commercial devices; 3) advancing shimming procedures to improve the homogeneity of the B0 field; 4) permitting high-resolution, multi-dimensional, multi-volume MRS exams with 100% structure-function correlation in reasonable scan times; 5) a stand-alone, easy-to-use program that provides the crucial link between multi-dimensional structural and multi-volume MRS acquisition, including its clinical and metabolic interpretation by effectively tackling the demanding spectral processing and analysis needs; and 6) a comprehensive MRI-MRS metrics system calibration, quality assurance and validation phantom essential to confirm reproducibility of measurements. Initially, we will demonstrate the research utility and clinical applicability by determining the structural and metabolic MRI-MRS parameter spread in healthy subjects. Results from this study will become essential to interpretation in subjects at higher risk of developing AD. This work builds upon our expertise in creating the first commercial dual- tuned 1H-31P 1.5T and 3T head coils (R44NS037273). This research also builds upon our work with the development of an automated B0 shimming program (FWHM 11.7 ± 1.9 Hz, n=94 at 1.5T) and the interactive MRS software. This project will offer 'A Complete Solution for the Early AD Detection’ with advanced brain MR assessments in the high-resolution structural and functional MRI exams, and multinuclear metabolic-based MRS acquisitions. Our licensed Siemens vendor agreement will propel the development and commercialization of the ADRD360. We aim to satiate the researchers by approaching the ultimate intrinsic SNR 31P and 1H limits on the 3T and 7T MR systems. We plan to demonstrate the clinical advantages by identifying critical structural and metabolic MR brain parameters that can be used as screening biomarkers in humans with mild cognitive impairment due to aging, AD, and related dementia. Confidential Proprietary Information Advanced Imaging Research dba SREE Medical Systems

NIH SBIR 快速通道，PAS-22-196 用于非侵入性表征的先进综合磁共振解决方案 没有临床试验阿尔茨海默病和痴呆症患者风险的高分辨率代谢生物标志物 项目概要 该项目致力于推进阿尔茨海默病 (AD) 和 AD 相关痴呆症的研究 (ADRD) 国家老龄化研究所的倡议 (PAS-22-196) 我们建议开发一种先进的方法。 硬件软件包 ADRD360，用于优化采集、处理和分析磁共振 ADRD360 将有助于定位人脑中的代谢。 签名并以比目前更高的分辨率获得 MRI 和 MRS 大脑数据 高分辨率的 MRI 和 MRS 对于早期诊断至关重要。 ADRD360 可以预测患 AD 的风险，从而实现结构性和功能性障碍的早期检测。 代谢参数作为 AD、ADRD 等患者的预测诊断工具生物标志物 该项目将为神经系统疾病和精神疾病提供完整的解决方案。 1) 接近最终本征的先进射频 (RF) 线圈的开发和优化 信噪比 (UISNR) 和可接受的比吸收率 (SAR) 2) 推动结构 MR； 超过商业设备的成像分辨率；3）改进匀场程序以提高 B0 场的同质性；4) 允许高分辨率、多维、多体积 MRS 检查 在合理的扫描时间内具有 100% 的结构-功能相关性；5) 独立、易于使用的程序； 它提供了多维结构和多体积 MRS 采集之间的关键联系， 通过有效废除苛刻的光谱处理来包括其临床和代谢解释 和分析需求；以及 6) 全面的 MRI-MRS 指标系统校准、质量保证和 验证模型对于确认测量的再现性至关重要。首先，我们将演示 通过确定结构和代谢 MRI-MRS 参数来实现研究效用和临床适用性 这项研究的结果对于解释在健康受试者中的情况至关重要。 这项工作建立在我们创建第一个商业双通道的专业知识之上。 调谐 1H-31P 1.5T 和 3T 头部线圈 (R44NS037273) 也建立在我们与 开发自动 B0 匀场程序（FWHM 11.7 ± 1.9 Hz，n=94 at 1.5T）和 该项目将提供“早期 AD 检测的完整解决方案”。 高分辨率结构和功能 MRI 检查中的高级脑 MR 评估，以及 我们授权的西门子供应商协议将推动基于多核代谢的 MRS 收购。 我们的目标是通过接触 ADRD360 来满足研究人员的需求。 我们计划演示 3T 和 7T MR 系统的最终固有 SNR 31P 和 1H 限制。 通过识别可使用的关键结构和代谢 MR 脑参数来获得临床优势 作为筛选因衰老、AD 和相关痴呆症而患有轻度认知障碍的人类的生物标志物。 机密专有信息 高级成像研究 dba SREE 医疗系统